Immunosuppressants - Finland

Finland

In Finland, the Immunosuppressants market is anticipated to achieve a revenue of US$71.15m by 2024.
It is projected to exhibit an annual growth rate (CAGR 2024-2029) of 14.90%, leading to a market volume of US$142.50m by 2029.
When compared globally, United States is expected to generate the highest revenue in the Immunosuppressants market, amounting to US$35,470.00m in 2024.
The demand for immunosuppressants in Finland has seen a significant increase due to the country's growing number of organ transplant surgeries.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Immunosuppressants in Finland has been steadily increasing over the years.

Customer preferences: Finland has a high prevalence of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and type 1 diabetes. These diseases require long-term treatment with Immunosuppressants, leading to a high demand for these drugs. Additionally, the aging population in Finland has also contributed to the growth of the Immunosuppressants market as older people are more prone to autoimmune diseases.

Trends in the market: The Immunosuppressants market in Finland is witnessing a shift towards the use of biologics. Patients are increasingly opting for biologics due to their high efficacy and fewer side effects compared to traditional Immunosuppressants. The market is also witnessing the entry of biosimilars, which are expected to drive down the cost of treatment and increase accessibility.

Local special circumstances: Finland has a strong public healthcare system, which covers a significant portion of the population. The government is also actively involved in the pricing and reimbursement of drugs, which has resulted in a highly regulated market. This has led to a slower adoption of new drugs in the market, as the government takes time to assess the cost-effectiveness of new treatments.

Underlying macroeconomic factors: Finland has a stable economy with a high GDP per capita. This has resulted in a higher disposable income, which has enabled patients to afford expensive Immunosuppressants. The government's focus on healthcare has also led to increased spending on drugs, further driving the growth of the Immunosuppressants market. However, the COVID-19 pandemic has had an impact on the market, as patients have delayed seeking medical attention and treatment, leading to a temporary slowdown in the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.